The Real Economic Impact of the MADIT-II Study on the European Medical Community
One of the most relevant problems in current cardiological practice is the possibility of implementing, in patients who have a specific indication, a series of treatments of proven efficacy but of high cost. This problem involves percutaneous transluminal coronary angioplasty (PTCA) and cardioverter-defibrillators (CDs) . Table 1 shows the number of procedures performed in the year 2000 in the European Union (15 countries) and in the whole of Europe (33 countries). As the table shows, the increase in population obtained by adding 18 countries to those within the European Union is not followed by a parallel increase in the number of high-cost procedures, suggesting marked difficulties due to economic reasons in using these treatments in routine daily practice.
KeywordsCardiac Resynchronization Therapy Implantation Rate Implantable Defibrillator Implantable Cardiac Defibrillator Multicenter Automatic Defibrillator Implantation Trial
Unable to display preview. Download preview PDF.
- 5.Gregoratos G, Abrams J, Epstein AE et al (2002) ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/NASPE committee to update the 1998 pacemaker guidelines). J Am Coll Cardiol 40:1703–1719PubMedCrossRefGoogle Scholar
- 8.Pathmanathan RK, Lau EW, Cooper J et al (1998) Potential impact of antiarrhythmic drugs versus implantable defibrillators on the management of ventricular arrhythmias: the Midlands trial of empirical amiodarone versus electrophysiologically guided intervention and cardioverter implant registry data. Heart 80:68–70PubMedGoogle Scholar
- 10.Boersma H, Doornbos G, Bloemberg BPM et al (1999) Cardiovascular diseases in Europe. European Society of Cardiology, Sophia Antipolis, France, pp 1–60Google Scholar
- 16.Bristow MR (2003) Cardiac resynchronization therapy reduces hospitalizations, and cardiac resynchronization therapy and implantable defibrillator reduce mortality in chronic heart failure. Results of the COMPANION trial. Late breaking clinical trials. American College of Cardiology, 52nd Annual Scientific Session, Chicago, 30 March to 2 April 2003Google Scholar